NNNN Stock Analysis: Buy, Sell, or Hold?
NNNN - Anbio Biotechnology Class A Ordinary Shares
$6.81
-0.52 (-7.09%)
▼
5d:
-22.08%
30d:
-30.08%
90d:
-77.49%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 07, 2026
0d
Get Alerted When NNNN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NNNN is down 22.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NNNN is down 22.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NNNN is currently trading at $6.81, which is considered oversold relative to its 30-day fair value range of $9.28 to $10.59.
Technical Outlook: Technically, NNNN is in a strong downtrend. The price is currently testing key support at $6.61. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: NNNN scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NNNN is in a strong downtrend. The price is currently testing key support at $6.61. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: NNNN scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.28 -
$10.59
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
47.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.1%)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$9.28 -
$10.59
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$6.61
Resistance Level
$13.80
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Revenue Growth (YoY)
73.9%
Earnings Growth (YoY)
2.8%
Profit Margin
74.1%
Share & Embed Analysis
Last updated: August 24, 2026 7:03 AM ET
Data refreshes hourly during market hours. Next update: 8:03 AM
Data refreshes hourly during market hours. Next update: 8:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NNNN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$478 | 46 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$85 | 37 SELL |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$405 | 66 BUY |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$186 | 45 HOLD |
|
RMD
ResMed Inc |
BUY
19 analysts |
$246 | 41 HOLD |
